

25 Years of Data Driven Solutions

The logo for CRAB (Cancer Research And Biostatistics) is centered within a large circle. The letters 'C', 'R', and 'A' are connected by thin lines to small star-like nodes, suggesting a network or data structure. The background of the entire page is a complex, radial pattern of blue lines and binary code (0s and 1s) that radiates outwards from the center, resembling a sunburst or a data visualization of connections.

CRAB

CANCER RESEARCH
AND BIostatISTICS

2022 Annual Report
Cancer Research And Biostatistics



Cancer Research And Biostatistics (CRAB) is a non-profit organization whose purpose is to help conquer cancer and other diseases through the application of biostatistical principles and innovative data management methods.

TABLE OF CONTENTS

4	MESSAGE FROM THE PRESIDENT
6	CRAB 25 th ANNIVERSARY
7	SWOG CANCER RESEARCH NETWORK
9	GENERATING BUZZ
11	COLLABORATIONS
12	OUR EMPLOYEES
13	COMMUNITY CONNECTIONS
15	LEADERSHIP & GOVERNANCE
17	FRIENDS & SUPPORTERS
18	AUDIT & FINANCIAL SUMMARY

MESSAGE FROM THE PRESIDENT

Antje Hoering, PhD



This past year, 2022, marked CRAB's 25th anniversary, a major milestone in our history. This was also a year of transitions, which came with challenges as well as new and exciting opportunities. We said good-bye to long-term employees, and board members and welcomed new board members, employees and promoted others who took on new roles and responsibilities. I am incredibly proud of CRAB's many achievements.

We began to emerge from the COVID-19 pandemic and returned from mostly remote work to a hybrid schedule of working at least two days each week in the office. This new hybrid schedule allows us to reconnect with our long-time colleagues, get to know new colleagues better and interact in-person – all while maintaining flexibility for our indispensable employees.

I'm happy that we were able to celebrate our 25th anniversary in person at the end of September. CRAB was co-founded by Drs. John and Cay Crowley in 1997. Many current and former employees, board members, friends and other collaborators – including many from the SWOG Cancer Research Network – joined us for a celebration. It was a beautiful fall afternoon and it was wonderful to reconnect with so many people from all walks of CRAB's life.

CRAB has many long-term employees – an extraordinary forty percent of our staff have more than ten years tenure. Six long-term employees with a combined service of 105+ years at CRAB retired during the year, including two officers: Bill Charters, our Chief Financial Officer (CFO) and Dr. Keith Goodman, our Chief Technology Officer (CTO). I'm grateful to all of our long-term employees for their many years of service to CRAB. I'm also grateful to our outgoing officers for making their transitions seamless.

These retirements also provided opportunities for advancement and new hires, who brought fresh perspectives and ideas. Damien Mar Chong started in the role of CFO in January and has hit the ground running. Chris Cook, who has been with CRAB for 17 years, transitioned from the role of Director of Applications Development to CTO in September. I'm very fortunate to have a dedicated leadership team that also includes Curt Malloy, Chief Operations Officer. The team brings expertise and hard work to help me strategize and work through challenges to accomplish our mission to help conquer cancer.

One highlight of 2022 was the SWOG S1800A trial, activated in May 2019, which led to a "breakthrough designation" by the U.S. Food and Drug Administration (FDA) for the combination of ramucirumab and pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). We are proud to have contributed to this study by providing the IT infrastructure and data management as a part of the SWOG Statistics and Data Management Center, co-located at the Fred Hutchinson Cancer Center and CRAB. This trial is one of several sub-studies of the National Cancer Institute's (NCI) Lung-MAP precision medicine master trial in lung cancer. We launched Lung-MAP in 2014 as the first master protocol funded by the NCI. The positive findings for S1800A also led to the development of a new trial, S2302 Pragmatica-Lung, to confirm the positive findings in a Phase 3 setting. S2302 is unique in its approach, as it was developed with a streamlined pragmatic trial design that includes a reduced set of eligibility criteria to allow many patients with advanced NSCLC to be eligible to participate in the trial. This trial is also unique in that it was developed in record time and our CRAB team is preparing for activation in Q1 2023.

CRAB's long-standing collaboration with the International Association for the Study of Lung Cancer (IASLC) and the Staging and Prognostic Factors Committee (SPFC) continued with work on the Ninth Edition of the Tumor, Node, Metastasis (TNM) classification system. Data from around the world related to lung cancer, mesothelioma and thymic malignancies diagnosed from 2011-2019 have been collected through batch datasets and using our proprietary electronic data capture system, CRAB Nebula™. Our statisticians have been mapping and analyzing data in conjunction with the SPFC to meet a goal of publishing the new edition in 2024.

Our collaboration with Friends of Cancer Research and its many partners from industry, academia and the FDA continue to assess whether changes in circulating tumor DNA are correlated to clinical outcome. CRAB serves as the Independent Analysis Center for this study, which could inform treatment decisions guided by less invasive tests measuring circulating tumor DNA. Step 2 of the ctMoniTR project builds on our earlier Step 1 collaboration, which was focused on NSCLC and immunotherapy. Step 2 includes more disease settings and different therapeutic interventions to determine whether the results from Step 1 can be generalized.

CRAB also collaborated on the launch of a new myeloma study this year. We work with Dr. Gareth Morgan, Professor of Medicine and Director of Myeloma Research at New York University, who is examining Smoldering Multiple Myeloma to "determine why Myeloma Incident rates for African Americans are different from European Americans." This work is funded by the NCI through an R01 grant. CRAB is pleased to provide statistical, application development and data management for this important study. Data collection forms are being hosted in CRAB Nebula™.

This year also involved changes in our Board of Directors. Two long-time members transitioned off from the board. I wish Cynthia Adkins and Angie Schroeder the best and thank them and all of our directors for their participation and support. We welcomed Roderic Davis, Relationship Manager at The Commerce Bank of Washington. Our board has a great mix of professionals with long-time experience with CRAB and some newer members all of whom generously volunteer their skills and expertise. We are also happy to have three others who may be interested in serving as board members.

I am proud to share with you our 2022 highlights and am excited and optimistic about the opportunities, potential and adventures that 2023 will bring!



Antje Hoering, PhD (she/her/hers)
President, Chair & CEO

Celebrating 25 years of data-driven solutions

Cancer Research And Biostatistics (CRAB) was founded by biostatistician John Crowley, PhD and psychologist Cay Crowley, PhD in 1997. Since its humble start 25 years ago, CRAB has become a pillar in the cancer research community.

All that CRAB has become is thanks to our staff, our Board of Directors, our collaborators and our supporters, who commit themselves every day to our mission of conquering cancer. Please join us in celebrating this anniversary and thanking everyone who has contributed to CRAB's success over the last 25 years. We look forward to many more years of memories and smiles together.

Browse our 25 Anniversary Booklet (https://www.crab.org/documents/CRAB_25.pdf) for an in-depth look at CRAB's accomplishments over the last 25 years!



Study Activations

CRAB's study builders activated six trials in 2022: S2101, S2200, S2108CD, S1900F, S2107, S1800D. Two of the studies, S2101 and S2108CD are of particular note. S2101 is the iMATCH pilot study and the NCI's first precision master protocol focused on immunotherapy. S2108CD is the first randomized controlled trial to measure the impact of an educationally enhanced genomic tumor board on both physician and patient outcomes. S2108CD collects data from both patients and physicians.

Lung-MAP and PRAGMATICA-Lung

In June 2022, positive results from Lung-MAP sub-study S1800A were presented at the American Society of Clinical Oncology Annual Meeting and published simultaneously in the *Journal of Clinical Oncology*. The results from this Phase II randomized study demonstrated significantly improved overall survival with ramucirumab/pembrolizumab, compared with standard of care in patients with advanced Non-Small Cell Lung Cancer (NSCLC) previously treated with an immune checkpoint inhibitor. This study provided positive news for treating patients that needed better options. The collaborative team that supported this trial included CRAB's Data Management, Applications Development and Central Monitoring departments – all of which put in many years of hard work to support the unique Lung-MAP trial infrastructure. Once this study was released, these teams went right back to work on the development of S2302 PRAGMATICA-LUNG, a streamlined Phase III study to follow-up on S1800A. The study activated in March 2023, less than a year after the publication of the S1800A manuscript! This study is unique in many ways: reducing eligibility and data-collection requirements in order to allow community sites to easily enroll into the study and it was developed in record-time.

Recruitment & Retention Committee Addresses Diversity, Equity & Inclusion in SWOG trials

The SWOG Recruitment and Retention Committee (RRC) advises on methods to increase participant accrual to SWOG trials, including a focus on underrepresented participants. CRAB's Clinical Trial Recruitment and Retention staff provide support and guidance to the RRC committee and to study teams. The RRC sponsors a "TAKE ACTION" series of educational symposia convening experts to share information about underrepresented populations for investigators, research professionals and all audiences during the SWOG semi-annual Group Meetings. The symposiums identify evidence-based practical strategies to ensure access and equity in SWOG clinical trials, address cultural values of specific populations that support building trust, reflect the current environment that a specific population is challenged with that impacts trial participation and recommends metrics to track overall progress. In 2022, "American Indians, Ensuring Equity in Clinical Research" and "Hispanic/Latinx Populations: Ensuring Equity in Clinical Research," were presented. The RRC also participates in and advises on a variety of other initiatives and diversity and inclusion activities across SWOG that encompass leadership, membership and clinical trial participation.

SWOG Latin America Initiative (SLAI) Continues to Fly!

In 2022, our Latin American collaborators continued recruiting to S1802, S1827, and S2013 – all while nearing activation of several other exciting trials. Three of our investigators are working with committees on developing or funding proposals. CRAB's SLAI Project Manager continues to provide Latin American Clinical Research Associates with regular online research trainings in Spanish.

SLAI's activities and scope continued to expand. Summer was the dawn of SLAI's biannual newsletter, highlighting activities, sites, and cancer among Hispanic populations. In autumn, SLAI traveled for a clinical trials training course focusing on cancer control, hosted by the member site in Montevideo, Uruguay. The year ended with the SWOG leadership team contemplating long-term strategies for SLAI's growth and sustainability.



2022 Central Monitoring

The CRAB central monitoring team's source document portal has a new look that was released by the Cancer Trials Support Unit (CTSU), a service of the National Cancer Institute (NCI). Released in 2022, the portal allows for the secure storage and management of essential clinical trial study documents. CRAB Central Monitors continue to collaborate with sites, data coordinators and auditors to ensure that research activities are within protocol parameters.

CRAB Data Management Facilitates Training Workshops at SWOG Group Meetings

SWOG held hybrid workshops in the spring and fall of 2022. This mechanism facilitated attendance both in-person and remotely, increasing our audience and addressing both challenges and opportunities. These were the first in-person meetings that also offered remote participation to most sessions since the COVID-19 pandemic began. The SWOG Clinical Trials Training Course was held in Seattle in spring 2022 with 95 attending in-person and 240 attending remotely. In the fall, CRAB staff led the eighth annual SWOG NCI Community Oncology Research Program (NCORP) Workshop in its first hybrid format. Investigators and clinical research professionals were provided training and information on a variety of topics related to conducting research in the areas of cancer survivorship, palliative and end of life care, prevention and epidemiology, symptom control and quality of life and cancer care delivery. This session had 90 in-person attendees and allowed 150 others to participate remotely. These workshops are made possible by the generous funding from The Hope Foundation for Cancer Research, a public charity that supports SWOG.

GENERATING BUZZ

19th Annual IMS Conference

In August, CRAB President and CEO, Antje Hoering, PhD, was invited to present at the 19th International Myeloma Society (IMS) Annual Meeting in Los Angeles. IMS is a professional, scientific and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (diagnosis and treatment), workshops, conferences and symposia on all aspects of multiple myeloma worldwide. Dr. Hoering presented on, "How do you Define Cure in Myeloma?"

ASH Clinical Research Training Institute

For the sixth-consecutive year, CRAB President and CEO, Antje Hoering, PhD, was invited to serve on the faculty for the American Society of Hematology's (ASH) Clinical Research Training Institute (CRTI). The training is a year-long education and mentoring program for fellows and junior faculty specializing in hematology. CRTI faculty mentor a handful of young professionals, providing individualized education and mentoring on clinical research methods, research collaborations, statistical analysis and career advancement at a week-long meeting in La Jolla, California. "This is a great way to help advance a Hematologist's career," said Antje.

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

In September, CRAB CEO, Antje Hoering, PhD, was invited to co-chair a roundtable at the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Dr. Hoering joined Dr. Hillary Stires from Friends of Cancer Research to facilitate a session, entitled "Evidentiary Roadmap for Use of ctDNA in Cancer Drug Development and as an Early Endpoint," and discussed the collaborative efforts on the ctMoniTR Project (see collaborations). Antje has a long-standing relationship with the American Statistical Association (ASA) having been a member since 1996. The important work being done by the ASA helps further the practice of statistics and helps us continue our fight against cancer.

CRAB Presents at Life Science Innovation Northwest Conference

CRAB presented at the Cellular, Laboratory & Manufacturing Services Session at the Life Science Innovation Northwest (LSINW) conference on Wednesday, April 20 held in Seattle, Washington. This was the first time we had seen our many colleagues across the region in an in-person venue. We value these connections with the Pacific Northwest's community of scientists, entrepreneurs and researchers from various healthcare or research organizations and institutions.





43rd Annual SCT Conference

CRAB's Chief Technology Officer, Chris Cook presented a poster at the 2022 Society for Clinical Trials. The poster was entitled "A More Efficient Approach to Clinical Trial Data Collection: The SWOG-nCartes Pilot Collaboration" and highlighted the potential time savings and data quality improvements to be potentially gained via the nCartes technology, which facilitates transfer of clinical data from a health system's Electronic Health Record (EHR) system to the controlled databases utilized in clinical trials. This poster received the meeting's Best Poster Presentation award!

IMS & FDA Joint Workshop

In November, CRAB President and CEO, Dr. Antje Hoering, was invited to serve as a panelist jointly with members of the International Myeloma Society (IMS) and the FDA at the Future of Drug Development in Multiple Myeloma Symposium, an FDA/IMS joint workshop. The workshop aimed to advance the future of drug development and discuss trial design, patient population and endpoints in the different multiple myeloma disease settings. CRAB is thrilled to help accelerate new promising therapies for myeloma patients while ensuring that these therapies are not too toxic and are truly beneficial.

NCI Childhood Cancer Data Initiative

Keith Goodman, CRAB Vice President of Technology, participated on a panel for National Cancer Institute (NCI) Childhood Cancer Data Initiative Workshop presenting on "The Importance of EHR Data in Clinical Care and Research." The workshop shared scientific and technical expertise related to EHR data used in childhood cancer research. Keith Goodman was a panelist for their discussion, "EHR-Directed Clinical Trials," where he shared his experience and understanding of EHR-to-EDC technology and processes. Keith's experience includes overseeing the recently conducted pilot project with SWOG Cancer Research Network to leverage the nCartes EHR-to-EDC data transfer tool. Early results from the pilot indicated that automating these processes can save study coordinator time and reduce data entry error. We value the expertise shared and appreciate being apart of these educational workshops.

Clin Ops Conference

CRAB was honored to have attended and presented at the Clinical Operations in Oncology Trials East Coast Conference July 19th and 20th in Boston, Massachusetts. This two-day event included panels, discussions, case studies and networking around clinical operations, technology and data management in oncology. Participating in these conferences allows us to connect with a wide array of industry professionals where we can share our knowledge and experience.

UAMS-NYU Myeloma Project

CRAB continued its collaboration with investigators at the Perlmutter Cancer Center at New York University Langone Health on a five-year project to study the mutational signatures, genetic patterns, and microbiomic features of African Americans and European Americans with smoldering myeloma, and to investigate whether established racial differences in rates of disease progression to symptomatic myeloma may be attributed to these features. The CRAB Nebula system was utilized to build the database for this multi-center clinical trial, with multiple study forms constructed, tested, and published. The protocol for the trial was reviewed and finalized with collaboration between CRAB and the study investigative team. The trial is anticipated to begin enrollment in the near future.

COLLABORATIONS

ctMoniTR

CRAB has served as the Independent Analysis Center for the Friends of Cancer Research (Friends) “ctDNA for Monitoring Treatment Response” (ctMoniTR) project since 2019. For the Step 1 pilot project, CRAB harmonized data from five studies and executed statistical analyses to determine if changes in circulating tumor DNA (ctDNA) could be an early indicator of a patient’s response to treatment with PD-L1 Immune Checkpoint Inhibitors. The results supported this hypothesis and were published in 2022 *JCO Precision Oncology*. CRAB has continued to work with Friends on the next phase of research. Step 2 builds on the results from Step 1, attempting to replicate the results in different treatments, different ctDNA assays, and different cancers. CRAB is excited to continue contributing to this impactful project which may help more-rapidly identify whether a therapy is working or whether a change to a different treatment is advised.

IASLC

CRAB, in partnership with the International Association for the Study of Lung Cancer (IASLC) and the Staging and Prognostic Factors Committee (SPFC), has continued its longstanding commitment to improving the Tumor, Node, Metastasis (TNM) classification system for the treatment of Lung Cancer. Our collective goal is to refine and advance this system to better serve patients and clinicians. As part of this ongoing effort, CRAB’s team of statisticians has been leading the charge, supported by our applications development, information technology, project management, and data management teams. Using our proprietary CRAB Nebula™ electronic data capture program, we have collected case data on lung cancer, mesothelioma, and thymic malignancies diagnosed from 2011-2019, with a focus on ensuring standardized data collection.

Our collaboration with IASLC has not only allowed us to work on the current ninth edition of the TNM classification system but also plan ahead for the tenth edition. We’re simultaneously strategizing and creating procedures to ensure that we’re well-prepared for the future. In August 2022, we were pleased to join lung cancer and thoracic oncology clinicians, researchers, and scientists from around the world in Vienna for the IASLC Staging Prognostic Factors Committee Meeting at the World Conference on Lung Cancer. During the event, we presented on our collaborative work, highlighting the progress we’ve made and the steps we’re taking to improve the TNM classification system.

Our team’s dedication to this important work underscores our commitment to improving patient outcomes through advanced data collection and classification. We look forward to continued collaboration with IASLC and SPFC, as we work to refine and enhance the TNM classification system for years to come.

DMC Services for Pharma Client

CRAB continues to offer its services to ensure the safety and effective management of clinical trials. This service is referred to as either a Data Monitoring Committee (DMC) or a Data Safety Monitoring Board (DSMB) and serves to assess whether critical efficacy endpoints of a clinical study are being appropriately monitored.

Our current client is conducting a randomized Phase 2 trial. As part of our services, CRAB is responsible for reviewing the DMC charter; programming tables, listings and figures; analyzing data; preparing and presenting reports for DMC members; and ensuring functional and productive meetings. We also provide operational support by a project manager that coordinates and schedules all DMC meetings, prepares and finalizes meeting minutes and interfaces between CRAB statistical resources, the DMC and the sponsor.

OUR EMPLOYEES

Caylene Castagno awarded the 2022 Cay Crowley Award for Excellence

Every year the CRAB Value's Committee reviews submission for the Cay Crowley Award for Excellence, named after our co-founder and former vice president and Chief Financial Officer, Cay Crowley, PhD. This year, Administrative Specialist Caylene Castagno won this prestigious award.

CRAB President and CEO Antje Hoering, PhD, presented the award at CRAB's All-Staff meeting in January 2022. Dr. Hoering cited several examples of Caylene's key contributions to CRAB, including leading the creation of CRAB's new quality management system, overseeing the migration of CRAB's travel process and invaluable contributions to several of CRAB committees.

Caylene was extolled for her professionalism, positive and constructive attitude, exceptional cooperation with colleagues and external parties, extraordinary attention to detail and steadfast commitment to social justice. Previous winners of this award are Dr. Cay Crowley (2015), Yoko Rivers (2016), Karen Anderson (2017), Laura Kingsbury (2018), Brent Watkins (2019), Dani Weatherbee (2020) and Matt Scott (2021).

Congratulations, Caylene!



Diversity, Equity and Inclusion and Workplace Committees

In 2022, CRAB established our Diversity, Equity and Inclusion (DEI) Committee, drafting and adopting a charter and selecting a leader and members.

Sponsored by our CEO and President, Antje Hoering, the DEI committee consists of ten committed staff members who are empowered to further CRAB's mission by fostering diversity, equity and inclusion within CRAB as an organization, support the healthcare industry at-large, as well as emphasize DEI in our local community. The Committee works to integrate best practices for diversity, equity and inclusion into the organizations policies and programs and serves as an advisory body to CRAB Management and other CRAB Committees. In the latter portion of 2022, the DEI Committee launched the DEI Personal Awareness Development Series – the first of this series planned for implementation in early 2023. At the end of the year, the Committee held its first retreat, planning out activities for the coming year.



We are very pleased to have this committee working on this essential issue and working in tandem with our various other committees, including our Values Committee, our Staff Appreciation Committee, our Lunch and Learn Committee and our Wellements Committee.

COMMUNITY CONNECTIONS

CRAB Cares Committee Renews Alliance Membership with Technology Access Foundation

On September 5th, Technology Access Foundation (TAF) (<https://techaccess.org>), joined CRAB at T-Mobile Park for a fundraising event focused on CRAB's Alliance Membership with TAF. As a Seattle-based non-profit, TAF is redefining K-12 public education across Washington State for students and teachers, particularly those who identify as a person of color and are from traditionally underserved communities. CRAB stands in strong support with TAF's mission and believes their work has wide-ranging benefits for the greater Seattle community as well as Washington's educational system. CRAB looks forward to expanding the partnership with TAF, especially the opportunity to bring student interns into our cancer research operations.



LEADERSHIP & GOVERNANCE

CRAB Executive Management Team


The year 2022 represented a significant transition for CRAB's executive leadership team.

In January, CRAB recruited a new Chief Financial Officer (CFO), Damien Mar Chong. Damien previously held the CFO roles at Lumetra Healthcare Solutions and at BALANCE/Consumer Credit Counseling Service of San Francisco. We were fortunate that our retiring CFO, Bill Charters, provided overlap and training during this transition.

Next, in September, CRAB announced the promotion of Chris Cook to the role of Chief Technology Officer (CTO). Due to his 17 year's of experience in various leadership roles at CRAB, Chris possesses a deep understanding of this essential function. Chris' prior role was CRAB's Director of Application Development. Once again, we were fortunate that our retiring CTO, Keith Goodman, provided overlap and training during this transition.

CRAB has two other Officers, Antje Hoering, PhD, our Chief Executive Officer, President and Board Chair – who has worked in various leadership roles at CRAB through her eighteen-year-tenure – and Curt Malloy, JD, MPH, our Chief Operating Officer, who has held this position for over six years, not including three years serving on CRAB's board.





LEADERSHIP & GOVERNANCE

New and retired board members

CRAB is extremely fortunate to have a board of directors that provides strategic input on our complex activities.

Our directors are all volunteers, assuming the responsibilities of reviewing our strategic plan; providing input on our goals, strategies and annual milestones; applying financial oversight and interfacing with our auditors to assess opportunities and risk; and assisting in building relationships with the cancer research community.

Our directors possess years of experience, often in life science research or in other critical areas that protect and promote CRAB's well-being – all while ensuring we are consistent with our mission, vision and values.

In 2022, two directors stepped away from the CRAB board at the end of their most recent three-year term, although they both remain available to assist and encourage us as we continue our journey.

Cynthia Adkins assisted CRAB leadership through a number of significant transitions, including during our search for a new Chief Executive Officer and President. Cindy is a well-known and highly admired member of the region's life science community, having served in various legal roles at the renowned start-up Immunex, then later establishing her own law firm. Cindy's belief in community service extends to acting as City Counsel Member – and, for various periods, as Mayor – at the City of Medina.

Angie Schroeder also provided guidance to CRAB as we sought new physical offices, adapted to the COVID-19 pandemic and transitioned to new Chief Financial and Chief Technology Officers. As a member of CRAB's Finance Committee, Angie also has deep experience in both for-profit and non-profit research institutes – leveraging previous experience at Corixa, Dendreon, the Infectious Disease Research Institute, Fred Hutch Cancer Center and currently at Seattle Children's Research Institute.

Cynthia and Angie, it has been a sincere pleasure working alongside you both. Thank you very much for your long-standing and impactful contributions to CRAB!

We are fortunate to announce a new member of CRAB's board of directors, Roderic Davis. Roderic immediately became an essential member of our Finance Committee, where he is leveraging over two decades' experience in financial management. Roderic is currently Relationship Manager at The Commerce Bank of Washington.

Roderic, we are fortunate to have you join our governance board – your insight immediately proved invaluable as we continually assess our financial well-being in light of a very dynamic economic landscape!

BOARD OF DIRECTORS



Antje Hoering, PhD
President, Board Chair & CEO
Cancer Research And Biostatistics



John J. Crowley, PhD
Chief of Strategic Alliances
Cancer Research And Biostatistics



Angie Schroeder, MBA
Director, Center Business Ops
Seattle Children's



Cynthia Adkins, JD
Partner & Founder
Adkins Black, LLP



David Gray, PhD, MBA
Consultant
Oncology Research & Development



Frank X. Curci, JD
Attorney & Shareholder
Buchalter



Gary Goodman, MD, MS
Senior Investigator
Swedish Tumor Institute
Fred Hutch



Michael LeBlanc, PhD
Group Statistician
Fred Hutch



Patrick Heagerty, PhD, MS
Biostatistics Professor
UW School of Public Health



Roderic Davis, MBA
Relationship Manager, Loan Officer
Commerce Bank of WA



Steve Snapinn, PhD
Independent Consultant




Tim Cummins
Managing Partner &
Chief Investment Officer
Sonata Capital Group

FRIENDS & SUPPORTERS


WE WOULD LIKE TO THANK THE MANY FRIENDS OF CRAB WHO MADE GENEROUS CONTRIBUTIONS IN SUPPORT OF OUR RESEARCH

- Aaron Schechter
- Amy Johnson
- Antje Hoering
- Curt Malloy
- Cynthia Adkins
- Dani Weatherbee
- David Gray
- John Crowley
- Julie Fox
- Kayla Burt
- Keith Goodman
- Laura Kingsbury
- Mike LeBlanc
- Phyllis Goodman
- Steve Snapinn
- Taylor Joosten
- William Barlow
- William Charters
- Amazon Smile
- Benevity Fund
- CAF America
- Fred Meyer Community Rewards
- Frontstream workplace Philanthropy
- King County Employee Giving Program
- Network For Good
- UKOGF Foundation

2022 FRIENDS & SUPPORTERS FORTHCOMING



AUDIT & FINANCIAL SUMMARY



2022 revenue grew 3% compared to the prior year. The increase in revenue was due to increases in SWOG grants. Revenue from all SWOG sources was 5% above the previous year reaching \$10,582,797 in 2022. Consistent funding led by our partners in the National Cancer Institute's National Cancer Trials Network sustained SWOG, and thus CRAB's federal funding in 2022; this was augmented by SWOG Clinical Trial Partner projects funded by pharma collaborators. Clinical and Statistical Research Program contract revenue continues to diversify revenues albeit at a lower level than previous years. Unrealized investment income in our reserves was negative in 2022.

Support and Revenue	2022	2021	2020	2019	2018
Grant	7,987,013	7,080,797	7,739,288	6,347,985	6,329,347
Contract	4,157,141	4,353,449	4,655,815	6,074,878	6,700,740
Patient/Site	0	63,890	61,893	224,675	265,866
Workshop	12,735	0	0	21,010	23,008
Contributions	9,647	13,039	9,592	11,683	18,693
Other	0	101	12,832	81,441	(27,147)
Investment	(173,406)	84,733	256,965	148,338	14,000
	\$11,993,130	\$11,596,009	\$12,736,385	\$12,910,010	\$13,324,507
Operating Expenses					
		2021	2020	2019	2018
Research	8,482,772	8,072,898	8,378,183	8,428,506	8,732,841
Workshops	12,063	3,308	832	21,011	23,008
Administration	3,628,826	3,711,171	2,902,275	3,769,381	4,270,035
	\$12,123,661	\$11,787,377	\$11,281,290	\$12,218,898	\$13,025,884

CANCER RESEARCH AND BIOSTATISTICS

OUR MISSION

is to help conquer cancer using the tools and expertise we bring to oncology clinical development:


Biostatistical principles


Oncology clinical trials expertise

Data management/monitoring services

Electronic data capture solutions

Education, support and training





1505 Westlake Ave N, STE 750
Seattle, WA 98109
(206) 652-9711 | www.crab.org
2022 All Rights Reserved
Report designed by Riley Williamson